Search This Blog

Thursday, January 30, 2020

Aprea Therapeutics nabs accelerated review status in U.S. for APR-246

Thinly traded Aprea Therapeutics (APRE -0.2%) announces Breakthrough Therapy status in the U.S. for lead candidate APR-246, combined with chemo agent azacitidine, for the treatment of myelodysplastic syndromes (MDS) with a susceptible TP53 mutation.
A Phase 2 study evaluating the combo as maintenance therapy after allogeneic hematopoietic stem cell transplant in patients with TP53-mutant MDS or AML is in process with an estimated primary completion date in July 2021.
The company says small molecule APR-246 reactivates the mutant form of the tumor suppressor protein p53.
https://seekingalpha.com/news/3536374-aprea-therapeutics-nabs-accelerated-review-status-in-u-s-for-aprminus-246

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.